Refine Results
- Products
- Content Type
-
Content Type
- Analysis Platform
-
Analysis Platform
- Language
-
Language
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Taiwan - Chinese (Traditional)
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 30 Sep 2022
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Taiwan - Chinese (Traditional)
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 17 Feb 2025
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Taiwan - Chinese (Traditional)
Released: 29 Aug 2021
-
Released: 29 Aug 2021
-
Released: 29 Aug 2021
This application note describes the characterization of product‑related impurities in the development of new oligonucleotide biotherapeutics using LC/(Q)-TOF and MassHunter BioConfirm software.
- Publication Part Number: 5994-4817EN
- Created: 13 May 2022
- 2 MB
